Literature DB >> 16227278

How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?

W David Wick1, Otto O Yang, Lawrence Corey, Steven G Self.   

Abstract

The antiviral role of CD8+ cytotoxic T lymphocytes (CTLs) in human immunodeficiency virus type 1 (HIV-1) infection is poorly understood. Specifically, the degree to which CTLs reduce viral replication by killing HIV-1-infected cells in vivo is not known. Here we employ mathematical models of the infection process and CTL action to estimate the rate that CTLs can kill HIV-1-infected cells from in vitro and in vivo data. Our estimates, which are surprisingly consistent considering the disparities between the two experimental systems, demonstrate that on average CTLs can kill from 0.7 to 3 infected target cells per day, with the variability in this figure due to epitope specificity or other factors. These results are compatible with the observed decline in viremia after primary infection being primarily a consequence of CTL activity and have interesting implications for vaccine design.

Entities:  

Mesh:

Year:  2005        PMID: 16227278      PMCID: PMC1262579          DOI: 10.1128/JVI.79.21.13579-13586.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.

Authors:  S M Kaech; R Ahmed
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

3.  HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death.

Authors:  S J Brodie; B K Patterson; D A Lewinsohn; K Diem; D Spach; P D Greenberg; S R Riddell; L Corey
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 4.  Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution.

Authors:  A B Lyons
Journal:  J Immunol Methods       Date:  2000-09-21       Impact factor: 2.303

5.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.

Authors:  D Wick; S G Self
Journal:  Math Biosci       Date:  2000-06       Impact factor: 2.144

7.  The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets.

Authors:  D M McKinney; D A Lewinsohn; S R Riddell; P D Greenberg; D E Mosier
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

8.  Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.

Authors:  T M Allen; D H O'Connor; P Jing; J L Dzuris; B R Mothé; T U Vogel; E Dunphy; M E Liebl; C Emerson; N Wilson; K J Kunstman; X Wang; D B Allison; A L Hughes; R C Desrosiers; J D Altman; S M Wolinsky; A Sette; D I Watkins
Journal:  Nature       Date:  2000-09-21       Impact factor: 49.962

9.  AIDS as immune system activation: a model for pathogenesis.

Authors:  M S Ascher; H W Sheppard
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

10.  Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.

Authors:  B D Walker; C Flexner; K Birch-Limberger; L Fisher; T J Paradis; A Aldovini; R Young; B Moss; R T Schooley
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

View more
  21 in total

1.  Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines.

Authors:  Ruijiang Song; Shuqin Liu; Kam W Leong
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

2.  Understanding the failure of CD8+ T-cell vaccination against simian/human immunodeficiency virus.

Authors:  Rob J De Boer
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

3.  Enhancing efficacy of HIV gag DNA vaccine by local delivery of GM-CSF in murine and macaque models.

Authors:  Ruijiang Song; Shuqin Liu; Robert J Adams; Kam W Leong
Journal:  J Interferon Cytokine Res       Date:  2006-06       Impact factor: 2.607

Review 4.  Modeling T cell responses to antigenic challenge.

Authors:  Dominik Wodarz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-01       Impact factor: 2.745

5.  Estimation of the rate of killing by cytotoxic T lymphocytes in vivo.

Authors:  Roland R Regoes; Daniel L Barber; Rafi Ahmed; Rustom Antia
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

6.  Estimating in vivo death rates of targets due to CD8 T-cell-mediated killing.

Authors:  Vitaly V Ganusov; Rob J De Boer
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

7.  Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo.

Authors:  W David Wick; Peter B Gilbert; Otto O Yang
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

8.  Estimating the effectiveness of simian immunodeficiency virus-specific CD8+ T cells from the dynamics of viral immune escape.

Authors:  Judith N Mandl; Roland R Regoes; David A Garber; Mark B Feinberg
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

9.  Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques.

Authors:  W David Wick; Otto O Yang
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

10.  Modelling HIV and MTB co-infection including combined treatment strategies.

Authors:  Santosh Ramkissoon; Henry G Mwambi; Alan P Matthews
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.